Adam Mead

Professor Adam Mead is a distinguished researcher and clinician, specializing in the genetic and cellular heterogeneity of myeloproliferative neoplasms (MPN) and related myeloid malignancies. He completed his medical and haematology training at the University of Oxford and University College London (UCL), where he also earned his PhD in 2007. Currently, he holds a CRUK Senior Cancer Research Fellowship, supporting his advanced research into these challenging forms of blood cancer.

 

The primary focus of Professor Mead’s research group is to elucidate the genetic and cellular diversity within MPN and related myeloid neoplasms. His team employs cutting-edge techniques in single-cell genomics and in vivo models to uncover previously unrecognized heterogeneity among cancer stem cells. Notably, their work has highlighted the crucial role of inflammation in driving therapy resistance and genetic evolution in these malignancies. The current research emphasis is on understanding the complex interactions between genetic, metabolic, and inflammatory factors in the clonal evolution of myeloid cancers.

 

Professor Mead’s research is closely integrated with his clinical practice at Oxford University Hospitals NHS Trust, where he serves as the myeloid clinical lead. He has been the principal or chief investigator in over 50 clinical trials and has played a pivotal role in the development of JAK2 inhibitor therapies in the UK. His leadership in key clinical trials, including ROBUST, MAJIC, MITHRIDATE, PERSIST-1 and -2, MPDRC114, PHAZAR, PAC203, FEDORA, and PROMise, has been instrumental in advancing treatment options for patients with MPN.